vs
GETTY REALTY CORP（GTY）与Vericel Corp（VCEL）财务数据对比。点击上方公司名可切换其他公司
Vericel Corp的季度营收约是GETTY REALTY CORP的1.6倍（$92.9M vs $57.8M），GETTY REALTY CORP净利率更高（46.0% vs 25.0%，领先21.0%），Vericel Corp同比增速更快（23.3% vs 10.5%），过去两年Vericel Corp的营收复合增速更高（34.6% vs 7.6%）
Getty Realty Corp是一家总部位于美国的上市房地产投资信托（REIT），主要持有、租赁并管理商业地产资产组合，核心资产涵盖便利店、加油站及配套零售物业，业务覆盖美国多个州，服务零售与能源领域的优质租户。
Vericel Corp是一家美国上市生物制药企业，前身为1989年在密歇根州安娜堡成立的Aastrom Bio，2014年10月正式更为现名，专注于生物制药相关领域的研发与商业化运营。
GTY vs VCEL — 直观对比
营收规模更大
VCEL
是对方的1.6倍
$57.8M
营收增速更快
VCEL
高出12.7%
10.5%
净利率更高
GTY
高出21.0%
25.0%
两年增速更快
VCEL
近两年复合增速
7.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $57.8M | $92.9M |
| 净利润 | $26.6M | $23.2M |
| 毛利率 | — | 78.7% |
| 营业利润率 | 66.1% | 24.1% |
| 净利率 | 46.0% | 25.0% |
| 营收同比 | 10.5% | 23.3% |
| 净利润同比 | 80.1% | 17.3% |
| 每股收益（稀释后） | $0.43 | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GTYVCEL
| Q1 26 | $57.8M | — | ||
| Q4 25 | $60.5M | $92.9M | ||
| Q3 25 | $55.6M | $67.5M | ||
| Q2 25 | $53.3M | $63.2M | ||
| Q1 25 | $52.3M | $52.6M | ||
| Q4 24 | $53.0M | $75.4M | ||
| Q3 24 | $51.5M | $57.9M | ||
| Q2 24 | $49.9M | $52.7M |
净利润GTYVCEL
| Q1 26 | $26.6M | — | ||
| Q4 25 | $27.0M | $23.2M | ||
| Q3 25 | $23.3M | $5.1M | ||
| Q2 25 | $14.0M | $-553.0K | ||
| Q1 25 | $14.8M | $-11.2M | ||
| Q4 24 | $22.3M | $19.8M | ||
| Q3 24 | $15.3M | $-901.0K | ||
| Q2 24 | $16.7M | $-4.7M |
毛利率GTYVCEL
| Q1 26 | — | — | ||
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% |
营业利润率GTYVCEL
| Q1 26 | 66.1% | — | ||
| Q4 25 | 67.3% | 24.1% | ||
| Q3 25 | 62.5% | 5.1% | ||
| Q2 25 | 46.7% | -3.2% | ||
| Q1 25 | 50.5% | -24.3% | ||
| Q4 24 | 61.6% | 24.5% | ||
| Q3 24 | 48.9% | -4.3% | ||
| Q2 24 | 52.5% | -11.5% |
净利率GTYVCEL
| Q1 26 | 46.0% | — | ||
| Q4 25 | 44.7% | 25.0% | ||
| Q3 25 | 42.0% | 7.5% | ||
| Q2 25 | 26.3% | -0.9% | ||
| Q1 25 | 28.3% | -21.4% | ||
| Q4 24 | 42.1% | 26.3% | ||
| Q3 24 | 29.8% | -1.6% | ||
| Q2 24 | 33.5% | -8.9% |
每股收益（稀释后）GTYVCEL
| Q1 26 | $0.43 | — | ||
| Q4 25 | $0.46 | $0.46 | ||
| Q3 25 | $0.40 | $0.10 | ||
| Q2 25 | $0.24 | $-0.01 | ||
| Q1 25 | $0.25 | $-0.23 | ||
| Q4 24 | $0.38 | $0.40 | ||
| Q3 24 | $0.27 | $-0.02 | ||
| Q2 24 | $0.30 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.7M | $137.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $354.6M |
| 总资产 | $2.2B | $488.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GTYVCEL
| Q1 26 | $3.7M | — | ||
| Q4 25 | $8.4M | $137.5M | ||
| Q3 25 | $5.2M | $135.4M | ||
| Q2 25 | $7.5M | $116.9M | ||
| Q1 25 | $6.3M | $112.9M | ||
| Q4 24 | $9.5M | $116.2M | ||
| Q3 24 | $4.0M | $101.7M | ||
| Q2 24 | $4.7M | $102.5M |
总债务GTYVCEL
| Q1 26 | — | — | ||
| Q4 25 | $995.0M | — | ||
| Q3 25 | $934.6M | — | ||
| Q2 25 | $919.2M | — | ||
| Q1 25 | $901.4M | — | ||
| Q4 24 | $904.3M | — | ||
| Q3 24 | $833.9M | — | ||
| Q2 24 | $838.4M | — |
股东权益GTYVCEL
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $354.6M | ||
| Q3 25 | $1.0B | $321.9M | ||
| Q2 25 | $982.4M | $306.8M | ||
| Q1 25 | $961.1M | $295.5M | ||
| Q4 24 | $962.1M | $292.0M | ||
| Q3 24 | $963.4M | $257.5M | ||
| Q2 24 | $951.0M | $243.0M |
总资产GTYVCEL
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $488.0M | ||
| Q3 25 | $2.1B | $453.3M | ||
| Q2 25 | $2.0B | $435.6M | ||
| Q1 25 | $2.0B | $424.6M | ||
| Q4 24 | $2.0B | $432.7M | ||
| Q3 24 | $1.9B | $390.4M | ||
| Q2 24 | $1.9B | $376.8M |
负债/权益比GTYVCEL
| Q1 26 | — | — | ||
| Q4 25 | 0.93× | — | ||
| Q3 25 | 0.92× | — | ||
| Q2 25 | 0.94× | — | ||
| Q1 25 | 0.94× | — | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 0.87× | — | ||
| Q2 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $15.0M |
| 自由现金流经营现金流 - 资本支出 | — | $12.8M |
| 自由现金流率自由现金流/营收 | — | 13.8% |
| 资本支出强度资本支出/营收 | — | 2.4% |
| 现金转化率经营现金流/净利润 | — | 0.65× |
| 过去12个月自由现金流最近4个季度 | — | $24.7M |
8季度趋势，按日历期对齐
经营现金流GTYVCEL
| Q1 26 | — | — | ||
| Q4 25 | $127.4M | $15.0M | ||
| Q3 25 | $30.5M | $22.1M | ||
| Q2 25 | $34.7M | $8.2M | ||
| Q1 25 | $28.7M | $6.6M | ||
| Q4 24 | $130.5M | $22.2M | ||
| Q3 24 | $34.6M | $10.2M | ||
| Q2 24 | $29.7M | $18.5M |
自由现金流GTYVCEL
| Q1 26 | — | — | ||
| Q4 25 | $127.0M | $12.8M | ||
| Q3 25 | $30.4M | $19.5M | ||
| Q2 25 | $34.6M | $81.0K | ||
| Q1 25 | $28.6M | $-7.6M | ||
| Q4 24 | $129.6M | $8.5M | ||
| Q3 24 | $34.4M | $-9.2M | ||
| Q2 24 | $29.6M | $1.8M |
自由现金流率GTYVCEL
| Q1 26 | — | — | ||
| Q4 25 | 209.8% | 13.8% | ||
| Q3 25 | 54.7% | 28.8% | ||
| Q2 25 | 64.9% | 0.1% | ||
| Q1 25 | 54.7% | -14.5% | ||
| Q4 24 | 244.5% | 11.2% | ||
| Q3 24 | 66.9% | -15.9% | ||
| Q2 24 | 59.2% | 3.4% |
资本支出强度GTYVCEL
| Q1 26 | — | — | ||
| Q4 25 | 0.7% | 2.4% | ||
| Q3 25 | 0.2% | 3.9% | ||
| Q2 25 | 0.3% | 12.9% | ||
| Q1 25 | 0.1% | 27.0% | ||
| Q4 24 | 1.7% | 18.3% | ||
| Q3 24 | 0.4% | 33.5% | ||
| Q2 24 | 0.3% | 31.8% |
现金转化率GTYVCEL
| Q1 26 | — | — | ||
| Q4 25 | 4.71× | 0.65× | ||
| Q3 25 | 1.31× | 4.35× | ||
| Q2 25 | 2.48× | — | ||
| Q1 25 | 1.94× | — | ||
| Q4 24 | 5.85× | 1.12× | ||
| Q3 24 | 2.26× | — | ||
| Q2 24 | 1.78× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GTY
暂无分部数据
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
